T 细胞优化移植物抗白血病反应。
T cell optimization for graft-versus-leukemia responses.
机构信息
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Department of Medicine, and.
出版信息
JCI Insight. 2020 May 7;5(9):134939. doi: 10.1172/jci.insight.134939.
Abstract
Protection from relapse after allogeneic hematopoietic cell transplantation (HCT) is partly due to donor T cell-mediated graft-versus-leukemia (GVL) immune responses. Relapse remains common in HCT recipients, but strategies to augment GVL could significantly improve outcomes after HCT. Donor T cells with αβ T cell receptors (TCRs) mediate GVL through recognition of minor histocompatibility antigens and alloantigens in HLA-matched and -mismatched HCT, respectively. αβ T cells specific for other leukemia-associated antigens, including nonpolymorphic antigens and neoantigens, may also deliver an antileukemic effect. γδ T cells may contribute to GVL, although their biology and specificity are less well understood. Vaccination or adoptive transfer of donor-derived T cells with natural or transgenic receptors are strategies with potential to selectively enhance αβ and γδ T cell GVL effects.
摘要
异基因造血细胞移植（HCT）后防止复发部分归因于供者 T 细胞介导的移植物抗白血病（GVL）免疫反应。尽管 HCT 受者仍普遍存在复发，但增强 GVL 的策略可显著改善 HCT 后的结果。具有 αβ T 细胞受体（TCR）的供者 T 细胞通过识别 HLA 匹配和不匹配 HCT 中的次要组织相容性抗原和同种抗原来介导 GVL。针对其他白血病相关抗原（包括非多态性抗原和新抗原）的特异性 αβ T 细胞也可能具有抗白血病作用。γδ T 细胞可能有助于 GVL，尽管其生物学和特异性了解较少。用天然或转基因受体对供者来源的 T 细胞进行疫苗接种或过继转移是具有选择性增强 αβ 和 γδ T 细胞 GVL 作用潜力的策略。
相似文献
1
T cell optimization for graft-versus-leukemia responses.T 细胞优化移植物抗白血病反应。
JCI Insight. 2020 May 7;5(9):134939. doi: 10.1172/jci.insight.134939.
2
Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.多中心分析表明，在 HLA 匹配的相关和无关造血干细胞移植后，次要组织相容性抗原对移植物抗宿主病和移植物抗肿瘤效应具有显著的临床影响。
Biol Blood Marrow Transplant. 2013 Aug;19(8):1244-53. doi: 10.1016/j.bbmt.2013.06.001. Epub 2013 Jun 10.
3
Minor histocompatibility antigens--targets of graft versus leukemia responses.次要组织相容性抗原——移植物抗白血病反应的靶点
Int J Hematol. 2002 Aug;76 Suppl 2:155-61. doi: 10.1007/BF03165108.
4
Adoptive transfer of allogeneic antigen-specific T cells.同种异体抗原特异性T细胞的过继转移。
Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):9-12. doi: 10.1016/j.bbmt.2005.10.025.
5
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.来自次要组织相容性抗原疫苗接种和病毒免疫供体的记忆 T 细胞可改善移植物抗白血病和免疫重建。
Blood. 2011 Nov 24;118(22):5965-76. doi: 10.1182/blood-2011-07-367011. Epub 2011 Sep 13.
6
Natural regulation of immunity to minor histocompatibility antigens.对次要组织相容性抗原免疫反应的自然调节。
J Immunol. 2007 Mar 15;178(6):3558-65. doi: 10.4049/jimmunol.178.6.3558.
7
Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation.次要组织相容性抗原预测、监测或调控异基因造血细胞移植后移植物抗白血病和移植物抗宿主病。
Best Pract Res Clin Haematol. 2024 Jun;37(2):101555. doi: 10.1016/j.beha.2024.101555. Epub 2024 May 15.
8
Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.次要组织相容性抗原作为移植物抗白血病反应的靶点。
Curr Opin Hematol. 2002 Nov;9(6):497-502. doi: 10.1097/00062752-200211000-00005.
9
Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.造血特异性T细胞对非造血组织的附带损害会在持续且强烈的移植物抗白血病反应过程中导致移植物抗宿主病。
Biol Blood Marrow Transplant. 2014 Jun;20(6):760-9. doi: 10.1016/j.bbmt.2014.03.002. Epub 2014 Mar 7.
10
Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.异基因造血细胞移植后针对次要组织相容性抗原的 T 细胞治疗复发白血病。
Blood. 2010 May 13;115(19):3869-78. doi: 10.1182/blood-2009-10-248997. Epub 2010 Jan 13.
引用本文的文献
1
Exercise-mobilized donor lymphocyte infusions enhanced with cytokine stimulation for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation.通过细胞因子刺激增强运动动员的供体淋巴细胞输注，用于预防和治疗异基因造血细胞移植后的白血病复发。
Front Immunol. 2025 Jun 12;16:1563972. doi: 10.3389/fimmu.2025.1563972. eCollection 2025.
2
A donor PD-1CD8 T-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease.由粒细胞集落刺激因子动员的供体PD-1 CD8 T样调节亚群可减轻受体急性移植物抗宿主病。
Signal Transduct Target Ther. 2025 Apr 2;10(1):120. doi: 10.1038/s41392-025-02183-1.
3
DNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantation.DNA条形码肽-MHC多聚体用于测量和监测异基因干细胞移植后次要组织相容性抗原特异性T细胞。
J Immunother Cancer. 2024 Dec 9;12(12):e009564. doi: 10.1136/jitc-2024-009564.
4
Framework for predicting alloreactivity in hematopoietic cell transplants.预测造血细胞移植中同种异体反应性的框架。
Nat Biotechnol. 2025 Jun;43(6):874-875. doi: 10.1038/s41587-024-02354-5.
5
Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment.开发用于癌症治疗的体内 CAR T 细胞疗法的进展和挑战。
EBioMedicine. 2024 Aug;106:105266. doi: 10.1016/j.ebiom.2024.105266. Epub 2024 Aug 1.
6
Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy.当前在增强嵌合抗原受体（CAR）T细胞制造方案及提高临床疗效的实验和计算方法方面取得的进展。
Front Mol Med. 2024 Feb 1;4:1310002. doi: 10.3389/fmmed.2024.1310002. eCollection 2024.
7
The Impact of Cryopreservation on Hematopoietic Stem Cell Engraftment and Post-transplant Outcome During the COVID-19 Pandemic.COVID-19 大流行期间，冷冻保存对造血干细胞植入和移植后结果的影响。
In Vivo. 2024 May-Jun;38(3):1271-1277. doi: 10.21873/invivo.13565.
8
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?同种异体嵌合抗原受体 T 细胞治疗技术：是否兑现了承诺？
Cells. 2024 Jan 12;13(2):146. doi: 10.3390/cells13020146.
9
Discovery of U2AF1 neoantigens in myeloid neoplasms.髓系肿瘤中 U2AF1 新抗原的发现。
J Immunother Cancer. 2023 Dec 12;11(12):e007490. doi: 10.1136/jitc-2023-007490.
10
The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后移植物抗白血病和移植物抗宿主病的微妙平衡。
Expert Rev Hematol. 2023 Jul-Dec;16(12):943-962. doi: 10.1080/17474086.2023.2273847. Epub 2023 Dec 18.
本文引用的文献
1
Neoantigens in Hematologic Malignancies.血液系统恶性肿瘤中的新生抗原。
Front Immunol. 2020 Feb 14;11:121. doi: 10.3389/fimmu.2020.00121. eCollection 2020.
2
'Off-the-shelf' allogeneic CAR T cells: development and challenges.现成的异体嵌合抗原受体 T 细胞：开发与挑战。
Nat Rev Drug Discov. 2020 Mar;19(3):185-199. doi: 10.1038/s41573-019-0051-2. Epub 2020 Jan 3.
3
Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.T 细胞耗竭的异基因造血干细胞移植后早期预防并发症的多抗原特异性 T 细胞的生成和输注：一项 I/II 期研究。
Leukemia. 2020 Mar;34(3):831-844. doi: 10.1038/s41375-019-0600-z. Epub 2019 Oct 17.
4
Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis.来自HLA匹配供者和替代供者的异基因造血干细胞移植的结局：欧洲血液与骨髓移植学会登记处的回顾性分析
Lancet Haematol. 2019 Nov;6(11):e573-e584. doi: 10.1016/S2352-3026(19)30158-9. Epub 2019 Aug 30.
5
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy.造血干细胞移植治疗成人急性淋巴细胞白血病：美国移植和细胞治疗学会 2019 年更新的循证综述。
Biol Blood Marrow Transplant. 2019 Nov;25(11):2113-2123. doi: 10.1016/j.bbmt.2019.08.014. Epub 2019 Aug 22.
6
Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies.髓系恶性肿瘤造血干细胞移植后早期复发的生存情况。
Eur J Haematol. 2019 Nov;103(5):491-499. doi: 10.1111/ejh.13315. Epub 2019 Aug 14.
7
T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes.T-Scan：一种用于系统发现 T 细胞表位的全基因组方法。
Cell. 2019 Aug 8;178(4):1016-1028.e13. doi: 10.1016/j.cell.2019.07.009.
8
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.AML 经匹配无关异基因造血细胞移植后复发时反复出现遗传 HLA 缺失。
Blood Adv. 2019 Jul 23;3(14):2199-2204. doi: 10.1182/bloodadvances.2019000445.
9
Tissue-Resident Memory T Cells in Cancer Immunosurveillance.肿瘤免疫监视中的组织驻留记忆 T 细胞
Trends Immunol. 2019 Aug;40(8):735-747. doi: 10.1016/j.it.2019.06.002. Epub 2019 Jun 26.
10
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.靶向 WT1 的 T 细胞受体基因治疗可预防移植后急性髓系白血病复发。
Nat Med. 2019 Jul;25(7):1064-1072. doi: 10.1038/s41591-019-0472-9. Epub 2019 Jun 24.
Zotero 插件